161 related articles for article (PubMed ID: 22651555)
1. Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development.
Agoram BM; van der Graaf PH
Bioanalysis; 2012 Jun; 4(10):1143-5. PubMed ID: 22651555
[No Abstract] [Full Text] [Related]
2. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
Yu XQ; Wilson AG
Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
[No Abstract] [Full Text] [Related]
3. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
4. Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development.
Woodcock J
Clin Pharmacol Ther; 2009 Jul; 86(1):12-4. PubMed ID: 19536116
[No Abstract] [Full Text] [Related]
5. Biomarkers in clinical drug development.
Gobburu JV
Clin Pharmacol Ther; 2009 Jul; 86(1):26-7. PubMed ID: 19536121
[TBL] [Abstract][Full Text] [Related]
6. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
Smith BJ
Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
[No Abstract] [Full Text] [Related]
7. Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery.
Shi J; Zha W
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):135-137. PubMed ID: 30136219
[No Abstract] [Full Text] [Related]
8. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
Oosterhuis B
Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development.
Van Der Graaf PH; Gabrielsson J
Future Med Chem; 2009 Nov; 1(8):1371-4. PubMed ID: 21426051
[No Abstract] [Full Text] [Related]
10. Flow cytometry-based biomarkers in translational medicine and drug development.
Litwin V; O'Gorman MR
J Immunol Methods; 2011 Jan; 363(2):101-2. PubMed ID: 20888828
[No Abstract] [Full Text] [Related]
11. Application of PBPK modelling in drug discovery and development at Pfizer.
Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
[TBL] [Abstract][Full Text] [Related]
12. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
Agoram BM; Demin O
Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!
Rostami-Hodjegan A; Tamai I; Pang KS
Biopharm Drug Dispos; 2012 Mar; 33(2):47-50. PubMed ID: 22351594
[No Abstract] [Full Text] [Related]
14. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
[TBL] [Abstract][Full Text] [Related]
15. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development.
Kearns GL
Biomark Med; 2010 Dec; 4(6):783-6. PubMed ID: 21133695
[No Abstract] [Full Text] [Related]
16. Multiscale modeling in drug discovery and development: future opportunities and present challenges.
Vicini P
Clin Pharmacol Ther; 2010 Jul; 88(1):126-9. PubMed ID: 20520608
[TBL] [Abstract][Full Text] [Related]
17. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.
Zhao P; Rowland M; Huang SM
Clin Pharmacol Ther; 2012 Jul; 92(1):17-20. PubMed ID: 22713733
[TBL] [Abstract][Full Text] [Related]
18. Impact of modeling and simulation: myth or fact?
Allerheiligen SR
Clin Pharmacol Ther; 2014 Oct; 96(4):413-5. PubMed ID: 25236663
[No Abstract] [Full Text] [Related]
19. The promise of imaging biomarkers.
Drug News Perspect; 2010 Mar; 23(2):119-23. PubMed ID: 20369077
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.
Colburn WA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1419-27. PubMed ID: 11185662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
